American Journal of Cardiovascular Drugs

, Volume 5, Issue 2, pp 83–91 | Cite as

Management of Diabetic Dyslipidemia

Need for Reappraisal of the Goals
Current Opinion


Cardiovascular disease is the leading cause of mortality among people with diabetes mellitus, accounting for 70% of all deaths. As the prevalence of diabetes increases significantly worldwide, greater attention must be focused on preventing cardiovascular events in this group. One contributor to this increased event rate is the characteristic pattern of dyslipidemia in diabetic patients, consisting of elevated serum triglyceride levels, decreased high-density lipoprotein levels, and an increased proportion of small, dense, low-density lipoproteins. Several pharmacologic agents have been used to treat this dyslipidemia including HMG-CoA reductase inhibitors, fibric acid derivatives, niacin (nicotinic acid), thiazolidinediones, and fish oils, as well as other non-pharmacologic measures. Currently, the most extensive data for a reduction in cardiovascular events in patients with diabetes exist for HMG-CoA reductase inhibitors. The results of these trials indicate that HMG-CoA reductase inhibitor therapy should be considered for all patients with diabetes at sufficient risk for cardiovascular events, regardless of serum low-density lipoprotein-cholesterol level. Several ongoing trials of various pharmacologic agents should help clarify the role of these agents alone and in combination with HMG-CoA reductase inhibitors in the management of diabetic dyslipidemia.



The preparation of this manuscript was supported by funding from the Donald W. Reynolds Foundation. Dr McGuire has received honoraria from Takeda and Pfizer, research support from Pfizer and Glaxo Smith Kline, and is a consultant to Takeda and Sankyo.


  1. 1.
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414–31PubMedCrossRefGoogle Scholar
  2. 2.
    Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population 1971–1993. Diabetes Care 1998; 21(7): 1138–45PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241(19): 2035–8PubMedCrossRefGoogle Scholar
  4. 4.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16(2): 434–44PubMedCrossRefGoogle Scholar
  5. 5.
    Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–34PubMedCrossRefGoogle Scholar
  6. 6.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-97Google Scholar
  7. 7.
    Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 2003; 108(12): 1527–32PubMedCrossRefGoogle Scholar
  8. 8.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287(19): 2570–81PubMedCrossRefGoogle Scholar
  9. 9.
    Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003; 92(4A): 27J–33JPubMedCrossRefGoogle Scholar
  10. 10.
    Goldberg IJ. Clinical review 124: diabetic dyslipidemia. Causes and consequences. J Clin Endocrinol Metab 2001; 86(3): 965–71PubMedCrossRefGoogle Scholar
  11. 11.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA). A multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–58PubMedCrossRefGoogle Scholar
  12. 12.
    Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20(4): 614–20PubMedCrossRefGoogle Scholar
  13. 13.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96PubMedCrossRefGoogle Scholar
  14. 14.
    Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159(22): 2661–7PubMedCrossRefGoogle Scholar
  15. 15.
    Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26(10): 2713–21PubMedCrossRefGoogle Scholar
  16. 16.
    The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. N Engl J Med 1998; 339: 1349–57CrossRefGoogle Scholar
  17. 17.
    Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105(12): 1424–8PubMedCrossRefGoogle Scholar
  18. 18.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341(6): 410–8PubMedCrossRefGoogle Scholar
  19. 19.
    Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet 2003; 361: 2005–16PubMedCrossRefGoogle Scholar
  20. 20.
    Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94(6): 2349–56PubMedCrossRefGoogle Scholar
  21. 21.
    Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995; 38(8): 959–67PubMedCrossRefGoogle Scholar
  22. 22.
    Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275(12): 8416–25PubMedCrossRefGoogle Scholar
  23. 23.
    Yost TJ, Froyd KK, Jensen DR, et al. Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. Metabolism 1995; 44(6): 786–90PubMedCrossRefGoogle Scholar
  24. 24.
    Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2): 213–9PubMedCrossRefGoogle Scholar
  25. 25.
    Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97(11): 1029–36PubMedCrossRefGoogle Scholar
  26. 26.
    Lamarche B, Despres JP, Moorjani S, et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995; 75(17): 1189–95PubMedCrossRefGoogle Scholar
  27. 27.
    Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361(9359): 777–80PubMedCrossRefGoogle Scholar
  28. 28.
    Hayek T, Azrolan N, Verdery RB, et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism: studies in transgenic mice. J Clin Invest 1993; 92(3): 1143–52PubMedCrossRefGoogle Scholar
  29. 29.
    Sibley SD, Palmer JP, Hirsch IB, et al. Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. J Clin Endocrinol Metab 2003; 88(7): 3379–84PubMedCrossRefGoogle Scholar
  30. 30.
    Gowri MS, Van der Westhuyzen DR, Bridges SR, et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19(9): 2226–33PubMedCrossRefGoogle Scholar
  31. 31.
    Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT: Multiple Risk Factor Intervention Trial. Am Heart J 1986; 112(4): 825–36PubMedCrossRefGoogle Scholar
  32. 32.
    Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256(20): 2835–8PubMedCrossRefGoogle Scholar
  33. 33.
    de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11(2): 298–306PubMedCrossRefGoogle Scholar
  34. 34.
    Vaisanen S, Baumstark MW, Penttila I, et al. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb Haemost 1997; 78(6): 1495–9PubMedGoogle Scholar
  35. 35.
    Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998; 138(2): 229–35PubMedCrossRefGoogle Scholar
  36. 36.
    Bjornheden T, Babyi A, Bondjers G, et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996; 123(1–2): 43–56PubMedCrossRefGoogle Scholar
  37. 37.
    Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95(1): 69–75PubMedCrossRefGoogle Scholar
  38. 38.
    Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276(11): 875–81PubMedCrossRefGoogle Scholar
  39. 39.
    Chapman MJ, Caslake M, Packard C, et al. New dimension of statin action on ApoB atherogenicity. Clin Cardiol 2003; 26 (1 Suppl. 1): I7–10PubMedCrossRefGoogle Scholar
  40. 40.
    Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 2003; 91(4A): 14B–22BPubMedCrossRefGoogle Scholar
  41. 41.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98(23): 2513–9PubMedCrossRefGoogle Scholar
  42. 42.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–22PubMedCrossRefGoogle Scholar
  43. 43.
    Sever PS, Dahlof B, Poulter NR, et al. ASCOT-LLA: questions about the benefits of atorvastatin (letter). Lancet 2003; 361: 1986–7CrossRefGoogle Scholar
  44. 44.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22CrossRefGoogle Scholar
  45. 45.
    Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98(19): 2088–93PubMedCrossRefGoogle Scholar
  46. 46.
    Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162(22): 2597–604PubMedCrossRefGoogle Scholar
  47. 47.
    Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45PubMedCrossRefGoogle Scholar
  48. 48.
    The Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357(9260): 905–10CrossRefGoogle Scholar
  49. 49.
    The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102(1): 21–7CrossRefGoogle Scholar
  50. 50.
    Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820–5PubMedCrossRefGoogle Scholar
  51. 51.
    Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16(6): 763–72PubMedCrossRefGoogle Scholar
  52. 52.
    Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994; 110(1): 1–11PubMedCrossRefGoogle Scholar
  53. 53.
    McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001; 88(3): 270–4PubMedCrossRefGoogle Scholar
  54. 54.
    Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162(14): 1568–76PubMedCrossRefGoogle Scholar
  55. 55.
    Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264(6): 723–6PubMedCrossRefGoogle Scholar
  56. 56.
    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study. A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284(10): 1263–70PubMedCrossRefGoogle Scholar
  57. 57.
    Clofibrate and niacin in coronary heart disease. JAMA 1975; 231 (4): 360-81Google Scholar
  58. 58.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8(6): 1245–55PubMedCrossRefGoogle Scholar
  59. 59.
    Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35(7–8): 908–17PubMedCrossRefGoogle Scholar
  60. 60.
    Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69(5): 340–5PubMedCrossRefGoogle Scholar
  61. 61.
    Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005 Jan; 95(1): 120–2PubMedCrossRefGoogle Scholar
  62. 62.
    Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91(8): 956–60PubMedCrossRefGoogle Scholar
  63. 63.
    Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25(7): 1198–202PubMedCrossRefGoogle Scholar
  64. 64.
    Wake Forest University School of Medicine, Public Health Sciences Department. Action to control cardiovascular risk in diabetes [online]. Available from URL: [Accessed 2004 Jun 28]Google Scholar
  65. 65.
    Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22): 1583–92PubMedCrossRefGoogle Scholar
  66. 66.
    Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93(3): 307–12PubMedCrossRefGoogle Scholar
  67. 67.
    Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512–7PubMedCrossRefGoogle Scholar
  68. 68.
    Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000; 355(9208): 1008–10PubMedCrossRefGoogle Scholar
  69. 69.
    Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003; 92(4A): 34J–41JPubMedCrossRefGoogle Scholar
  70. 70.
    Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90(9): 947–52PubMedCrossRefGoogle Scholar
  71. 71.
    Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24(2): 308–15PubMedCrossRefGoogle Scholar
  72. 72.
    Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25(4): 708–11PubMedCrossRefGoogle Scholar
  73. 73.
    Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25(4): 1074–95PubMedCrossRefGoogle Scholar
  74. 74.
    Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003; 107(4): 636–42PubMedCrossRefGoogle Scholar
  75. 75.
    Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111(3): 185–91PubMedCrossRefGoogle Scholar
  76. 76.
    Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107(19): 2409–15PubMedCrossRefGoogle Scholar
  77. 77.
    Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40(12): 2125–34PubMedCrossRefGoogle Scholar
  78. 78.
    Stroup JS, Kane MP, Busch RS. The antilipidemic effects of ezetimibe in patients with diabetes. Diabetes Care 2003; 26(10): 2958–9PubMedCrossRefGoogle Scholar
  79. 79.
    Petersen M, Pedersen H, Major-Pedersen A, et al. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002; 25(10): 1704–8PubMedCrossRefGoogle Scholar
  80. 80.
    Friday KE, Childs MT, Tsunehara CH, et al. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989; 12(4): 276–81PubMedCrossRefGoogle Scholar
  81. 81.
    Montori VM, Farmer A, Wollan PC, et al. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000; 23(9): 1407–15PubMedCrossRefGoogle Scholar
  82. 82.
    Glauber H, Wallace P, Griver K, et al. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108(5): 663–8PubMedGoogle Scholar
  83. 83.
    Friedberg CE, Janssen MJ, Heine RJ, et al. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998; 21(4): 494–500PubMedCrossRefGoogle Scholar
  84. 84.
    Hu FB, Cho E, Rexrode KM, et al. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003; 107(14): 1852–7PubMedCrossRefGoogle Scholar
  85. 85.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333(9): 541–9PubMedCrossRefGoogle Scholar
  86. 86.
    Taskinen MR, Kuusi T, Helve E, et al. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988; 8(2): 168–77PubMedCrossRefGoogle Scholar
  87. 87.
    Romano G, Patti L, Innelli F, et al. Insulin and sulfonylurea therapy in NIDDM patients: are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes 1997; 46(10): 1601–6PubMedCrossRefGoogle Scholar
  88. 88.
    Duvillard L, Pont F, Florentin E, et al. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with noninsulin-dependent diabetes mellitus. Diabetologia 2000; 43(1): 27–35PubMedCrossRefGoogle Scholar
  89. 89.
    Rivellese AA, Patti L, Romano G, et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subtractions in type 2 diabetic patients. J Clin Endocrinol Metab 2000; 85(11): 4188–92PubMedCrossRefGoogle Scholar
  90. 90.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1999; 354 (9178): 602]. Lancet 1998; 352(9131): 837–53CrossRefGoogle Scholar
  91. 91.
    Yamanouchi K, Shinozaki T, Chikada K, et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care 1995; 18(6): 775–8PubMedCrossRefGoogle Scholar
  92. 92.
    Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992; 15(11): 1690–3PubMedCrossRefGoogle Scholar
  93. 93.
    Boudou P, de Kerviler E, Erlich D, et al. Exercise training-induced triglyceride lowering negatively correlates with DHEA levels in men with type 2 diabetes. Int J Obes Relat Metab Disord 2001; 25(8): 1108–12PubMedCrossRefGoogle Scholar
  94. 94.
    Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30(4): 883–907PubMedCrossRefGoogle Scholar
  95. 95.
    Kishimoto H, Taniguchi A, Fukushima M, et al. Effect of short-term low-intensity exercise on insulin sensitivity, insulin secretion, and glucose and lipid metabolism in non-obese Japanese type 2 diabetic patients. Horm Metab Res 2002; 34(1): 27–31PubMedCrossRefGoogle Scholar
  96. 96.
    Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000; 132(8): 605–11PubMedGoogle Scholar
  97. 97.
    Tanasescu M, Leitzmann MF, Rimm EB, et al. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107(19): 2435–9PubMedCrossRefGoogle Scholar
  98. 98.
    Hu FB, Stampfer MJ, Solomon C, et al. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001; 134(2): 96–105PubMedGoogle Scholar
  99. 99.
    Grundy SM, Garber A, Goldberg R, et al. Prevention Conference VI: diabetes and Cardiovascular Disease. Writing Group IV: lifestyle and medical management of risk factors. Circulation 2002; 105(18): e153–158PubMedCrossRefGoogle Scholar
  100. 100.
    Frost G, Leeds AA, Dore CJ, et al. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 1999; 353(9158): 1045–8PubMedCrossRefGoogle Scholar
  101. 101.
    Jarvi AE, Karlstrom BE, Granfeldt YE, et al. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 1999; 22(1): 10–8PubMedCrossRefGoogle Scholar
  102. 102.
    Grundy SM. The optimal ratio of fat-to-carbohydrate in the diet. Annu Rev Nutr 1999; 19: 325–41PubMedCrossRefGoogle Scholar
  103. 103.
    Gonzelez C, Stern MP, Mitchell BD, et al. Clinical characteristics of type II diabetic subjects consuming high versus low carbohydrate diets in Mexico City and San Antonio, Texas. Diabetes Care 1994; 17(5): 397–404PubMedCrossRefGoogle Scholar
  104. 104.
    Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994; 271(18): 1421–8PubMedCrossRefGoogle Scholar
  105. 105.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–39PubMedCrossRefGoogle Scholar
  106. 106.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S15–35CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Division of Cardiology and the Donald W. Reynolds Cardiovascular Clinical Research CenterUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations